We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Antigen Improves Detection of Anti-Borrelia Antibodies

By LabMedica International staff writers
Posted on 25 Mar 2013
A recombinant antigen has been developed which greatly increases the specificity of anti-Borrelia antibody detection in the diagnosis of Lyme disease. More...


The dimeric outer surface protein C (OspC antigen) provides over 30% higher specificity than traditionally used monomeric forms, while maintaining a high sensitivity, especially in early stage infections.

Recombinant OspC has, for the first time, has been produced in dimeric form using state-of-the-art molecular biological methods. The dimeric OspC advanced antigen demonstrates the same characteristics as the native dimeric protein. Its exceptionally high specificity minimizes the risk of false-positive results and at the same time, it retains a high sensitivity.

Scientists at EUROIMMUN (Luebeck, Germany) have successfully produced recombinant, covalently bound dimeric OspC using genetic techniques which in contrast to native protein which is difficult to isolate, recombinant OspC advanced can be produced using standardized methods, ensuring a highly consistent antigen quality. The OspC advanced antigen improves the performance of both enzyme-linked immunosorbent assays (ELISA) and immunoblots for Borrelia diagnostics.

The Anti-Borrelia Select ELISA immunoglobulin M (IgM), which contains OspC advanced and other diagnostically relevant antigens in its antigenic substrate, provides exceptionally high sensitivity and specificity in the screening step for early-stage borreliosis. The confirmatory immunoblot Anti-Borrelia EUROLINE-RN-AT-adv (IgM), which includes OspC advanced from four different human pathogenic species, Borrelia afzelii, B. burgdorferi, B. garinii, and B. spielmanii, together with the outer surface protein of B. burgdorferi, known as VlsE, and other highly specific antigens, ensures accurate and reliable results in the confirmation of infections.

Antibodies against OspC are found in up to 90% of persons infected with Borrelia and represent the most important marker for early-stage borreliosis. Over 65,400 cases of Lyme borreliosis occur in Europe each year and over 27,000 cases were reported from the USA in 2012. The Anti-Borrelia Select ELISA and the Anti-Borrelia EUROLINE-RN-AT-adv are fast and easy to perform and can be fully automated, making them ideal for use in routine diagnostics.

Related Links:

EUROIMMUN




Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.